Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates

Loria, Paola; Lonardo, Amedeo; Leonardi, Francesca; Fontana, C.; Carulli, Lucia; Verrone, A; Borsatti, A; Bertolotti, Marco; Cassani, F.; Bagni, Alberto; Muratori, Paolo; Ganazzi, Dorval; Bianchi, Francesco; Carulli, Nicola

doi:10.1023/b:ddas.0000004522.36120.08

Cited by 128 publications

(106 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liver biopsy evaluation is also important for a patient with a clinical suspicion of autoimmune liver disease. Up to 20% of NAFLD have positive serologies for antinuclear antibody, antismooth muscle antibody, and/or antimitochondrial antibody [36][37][38] ; therefore, liver biopsy evaluation might be the only means of determining the underlying cause of the disease. Furthermore, surgeons have shown that intraoperative visualization is commonly not correct for the prediction of either steatosis or advanced fibrosis, and thus liver biopsy is currently being recommended in the morbidly obese bariatric population at the time of surgery [39] .…”

Section: Value Of Liver Biopsy Evaluation In Nonalcoholic Fatty Livermentioning

confidence: 99%

Histopathology of Non-Alcoholic Fatty Liver Disease

Brunt

2009

Clinics in Liver Disease

115

View full text Add to dashboard Cite

Histological analysis of liver biopsies remains a standard against which other methods of assessment for the presence and amount of hepatic injury due to nonalcoholic fatty liver disease (NAFLD) are measured. Histological evaluation remains the sole method of distinguishing steatosis from advanced forms of NAFLD, i.e. nonalcoholic steatohepatitis (NASH) and fibrosis. Included in the lesions of NAFLD are steatosis, lobular and portal inflammation, hepatocyte injury in the forms of ballooning and apoptosis, and fibrosis. However, patterns of these lesions are as distinguishing as the lesions themselves. Liver injury in adults and children due to NAFLD may have different histological patterns. In this review, the rationale for liver biopsy, as well as the histopathological lesions, the microscopically observable patterns of injury, and the differential diagnoses of NAFLD and NASH are discussed.

show abstract

Section: Value Of Liver Biopsy Evaluation In Nonalcoholic Fatty Livermentioning

confidence: 99%

Histopathology of Non-Alcoholic Fatty Liver Disease

Brunt

2009

Clinics in Liver Disease

115

View full text Add to dashboard Cite

show abstract

“…Elevated C-reactive protein (CRP) concentrations are related to insulin resistance, to MS, predict coronary heart disease, diabetes and have also been reported in NAFLD. 16,17 A high prevalence of nonorgan-specific autoantibodies, has been found in NAFLD associated with insulin resistance 18 and in patients with coronary atherosclerosis as well. 19 These data indicate that systemic subclinical inflammation typically associated with MS are also found in NAFLD.…”

Section: Pathogenesismentioning

confidence: 99%

Review article: the metabolic syndrome and non‐alcoholic fatty liver disease

Loria

Lonardo

Carulli

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYMetabolic syndrome represents a common risk factor for premature cardiovascular disease and cancer whose core cluster includes diabetes, hypertension, dyslipidaemia and obesity. The liver is a target organ in metabolic syndrome patients in which it manifests itself with nonalcoholic fatty liver disease spanning steatosis through hepatocellular carcinoma via steatohepatitis and cirrhosis. Given that metabolic syndrome and non-alcoholic fatty liver disease affect the same insulin-resistant patients, not unexpectedly, there are amazing similarities between metabolic syndrome and non-alcoholic fatty liver disease in terms of prevalence, pathogenesis, clinical features and outcome. The available drug weaponry for metabolic syndrome includes aspirin, metformin, peroxisome proliferator-activated receptor agonists, statins, ACE (angiotensin I-converting enzyme) inhibitors and sartans, which are potentially or clinically useful also to the non-alcoholic fatty liver disease patient. Studies are needed to highlight the grey areas in this topic. Issues to be addressed include: diagnostic criteria for metabolic syndrome; nomenclature of non-alcoholic fatty liver disease; enlargement of the clinical spectrum and characterization of the prognosis of insulin resistance-related diseases; evaluation of the most specific clinical predictors of metabolic syndrome/non-alcoholic fatty liver disease and assessment of their variability over the time; characterization of the importance of new risk factors for metabolic syndrome with regard to the development and progression of non-alcoholic fatty liver disease.

show abstract

“…Loria and colleagues documented that the high titers of ANA may be an indicator for a severe insulin resistance in those patients [71].…”

Section: ) Clinical Significance Of Autoimmunity In Liver Diseases Amentioning

confidence: 99%

Relationship between Autoimmunity and Cancer or Metabolic Abnormality in Liver Diseases

Himoto¹,

Nishioka²,

Masaki³

2014

TOAUTOJ

View full text Add to dashboard Cite

Recent advances in the serological analysis of recombinant cDNA expression libraries and proteomic analysis have enabled the identification of numerous kinds of novel autoantigens, especially tumor-associated antigens (TAAs). The emergence of antibodies to TAAs might imply that an autoimmune response was involved in the malignant transformation. These autoantibodies to TAAs often have predictive value as well as diagnostic relevance. Similarly, the relationship between autoimmunity and metabolic abnormalities, including insulin resistance and hepatic steatosis, has been also documented. Metabolic abnormalities are frequently associated with autoimmune diseases. In contrast, autoimmune reactions were occasionally involved in the process of metabolic dysregulation. This review primarily focuses on the current trends for the relationship between autoimmunity and cancer or metabolic abnormalities in liver disease and the current interpretations of autoantibodies in those diseases.

show abstract

Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates

Cited by 128 publications

References 45 publications

Histopathology of Non-Alcoholic Fatty Liver Disease

Histopathology of Non-Alcoholic Fatty Liver Disease

Review article: the metabolic syndrome and non‐alcoholic fatty liver disease

Relationship between Autoimmunity and Cancer or Metabolic Abnormality in Liver Diseases

Contact Info

Product

Resources

About